Literature DB >> 32768525

UDP-glucose 6-dehydrogenase knockout impairs migration and decreases in vivo metastatic ability of breast cancer cells.

Shao Thing Teoh1, Martin P Ogrodzinski2, Sophia Y Lunt3.   

Abstract

Dysregulated metabolism is a hallmark of cancer that supports tumor growth and metastasis. One understudied aspect of cancer metabolism is altered nucleotide sugar biosynthesis, which drives aberrant cell surface glycosylation known to support various aspects of cancer cell behavior including migration and signaling. We examined clinical association of nucleotide sugar pathway gene expression and found that UGDH, encoding UDP-glucose 6-dehydrogenase which catalyzes production of UDP-glucuronate, is associated with worse breast cancer patient survival. Knocking out the mouse homolog Ugdh in highly-metastatic 6DT1 breast cancer cells impaired migration ability without affecting in vitro proliferation. Further, Ugdh-KO resulted in significantly decreased metastatic capacity in vivo when the cells were orthotopically injected in syngeneic mice. Our experiments show that UDP-glucuronate biosynthesis is critical for metastasis in a mouse model of breast cancer.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Year:  2020        PMID: 32768525     DOI: 10.1016/j.canlet.2020.07.031

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  8 in total

1.  Investigation of the effects of downregulation of jumping translocation breakpoint (JTB) protein expression in MCF7 cells for potential use as a biomarker in breast cancer.

Authors:  Madhuri Jayathirtha; Anca-Narcisa Neagu; Danielle Whitham; Shelby Alwine; Costel C Darie
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

2.  Integrated Multi-Omics Data Analysis Reveals Associations Between Glycosylation and Stemness in Hepatocellular Carcinoma.

Authors:  Peiyan Liu; Qi Zhou; Jia Li
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

Review 3.  Mechanisms of coordinating hyaluronan and glycosaminoglycan production by nucleotide sugars.

Authors:  Brenna M Zimmer; Joseph J Barycki; Melanie A Simpson
Journal:  Am J Physiol Cell Physiol       Date:  2022-04-20       Impact factor: 5.282

4.  Investigating the role of endogenous estrogens, hormone replacement therapy, and blockade of estrogen receptor-α activity on breast metabolic signaling.

Authors:  Alana A Arnone; J Mark Cline; David R Soto-Pantoja; Katherine L Cook
Journal:  Breast Cancer Res Treat       Date:  2021-08-26       Impact factor: 4.872

5.  Dysregulated glucuronic acid metabolism exacerbates hepatocellular carcinoma progression and metastasis through the TGFβ signalling pathway.

Authors:  Qingzhu Gao; Bin Cheng; Chang Chen; Chong Lei; Xue Lin; Dan Nie; Jingjing Li; Luyi Huang; Xiaosong Li; Kai Wang; Ailong Huang; Ni Tang
Journal:  Clin Transl Med       Date:  2022-08

6.  NMR-based metabolomic analysis identifies RON-DEK-β-catenin dependent metabolic pathways and a gene signature that stratifies breast cancer patient survival.

Authors:  Sara Vicente-Muñoz; Brian G Hunt; Taylor E Lange; Susanne I Wells; Susan E Waltz
Journal:  PLoS One       Date:  2022-09-06       Impact factor: 3.752

7.  Multi-Omics Analysis Revealed a Significant Alteration of Critical Metabolic Pathways Due to Sorafenib-Resistance in Hep3B Cell Lines.

Authors:  Kholoud Y I Abushawish; Sameh S M Soliman; Alexander D Giddey; Hamza M Al-Hroub; Muath Mousa; Karem H Alzoubi; Waseem El-Huneidi; Eman Abu-Gharbieh; Hany A Omar; Sara M Elgendy; Yasser Bustanji; Nelson C Soares; Mohammad H Semreen
Journal:  Int J Mol Sci       Date:  2022-10-09       Impact factor: 6.208

8.  UDP-glucose dehydrogenase expression is upregulated following EMT and differentially affects intracellular glycerophosphocholine and acetylaspartate levels in breast mesenchymal cell lines.

Authors:  Qiong Wang; Sigurdur Trausti Karvelsson; Freyr Johannsson; Arnar Ingi Vilhjalmsson; Lars Hagen; Davi de Miranda Fonseca; Animesh Sharma; Geir Slupphaug; Ottar Rolfsson
Journal:  Mol Oncol       Date:  2022-02-03       Impact factor: 7.449

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.